GPP
FOMX

Great Point Partners’s Foamix Pharmaceuticals Ltd. Ordinary Shares FOMX Stock Holding History

Great Point Partners’s Portfolio FOMX Stock Details FOMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-2,110,071
Closed -$5.02M – 45
2019
Q2 		$5.02M Sell
2,110,071
-587,062
-22% -$1.75M 0.56% 23
2019
Q1 		$10.1M Sell
2,697,133
-1,350,428
-33% -$5.06M 1% 27
2018
Q4 		$14.5M Buy
4,047,561
+17,293
+0.4% +$75.2K 1.84% 19
2018
Q3 		$23.1M Sell
4,030,268
-751,440
-16% -$4.3M 3.6% 14
2018
Q2 		$24M Hold
4,781,708
– – 3.32% 14
2018
Q1 		$24.5M Hold
4,781,708
– – 3.64% 13
2017
Q4 		$28.7M Hold
4,781,708
– – 4.9% 8
2017
Q3 		$26.5M Hold
4,781,708
– – 5.16% 7
2017
Q2 		$22.2M Buy
4,781,708
+1,100,000
+30% +$4.91M 3.97% 10
2017
Q1 		$18.2M Buy
3,681,708
+681,708
+23% +$6.56M 3.62% 12
2016
Q4 		$33.3M Buy
3,000,000
+230,575
+8% +$2.17M 6.84% 2
2016
Q3 		$25.6M Buy
2,769,425
+2,494,669
+908% +$20.9M 6.54% 5
2016
Q2 		$1.75M Buy
+274,756
New +$1.82M 0.5% 27

Other funds holding FOMX

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
DA
DSC Advisors Chicago, Illinois $11M AUM 5.88% 1-Year Est. Return
Axa
Axa Paris, France $256M AUM 25.01% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
SM
Senvest Management New York $3.01B AUM 35.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DAM
DLD Asset Management New York $1.1B AUM 4.68% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Great Point Partners's FOMX Position: Q3 2019 in Review

Great Point Partners sold out of Foamix Pharmaceuticals Ltd. Ordinary Shares (FOMX) in Q3 2019, closing a stake of 2,110,071 shares — an estimated $5.02M sold.

Great Point Partners first reported a position in FOMX in Q2 2016 and held it in 13 quarters. The position peaked at $33.3M in Q4 2016. 59 funds tracked by Wall St. Rank hold FOMX as of Q3 2019.

  • Great Point Partners reported no remaining Foamix Pharmaceuticals Ltd. Ordinary Shares position as of Q3 2019 after selling out during the quarter.
  • Great Point Partners sold 2,110,071 Foamix Pharmaceuticals Ltd. Ordinary Shares shares in Q3 2019, an estimated $5.02M.
  • Great Point Partners first reported a position in Foamix Pharmaceuticals Ltd. Ordinary Shares in Q2 2016 and held it in 13 quarters.
  • Great Point Partners's Foamix Pharmaceuticals Ltd. Ordinary Shares position peaked at $33.3M in Q4 2016.
  • 59 funds tracked by Wall St. Rank held Foamix Pharmaceuticals Ltd. Ordinary Shares as of Q3 2019.

Based on Great Point Partners's 13F filing for Q3 2019, filed 15 Nov 2019.